June
Optimising the Benefit of Secondary Prevention: An LSE case study
Using population health, patient stratification and real-world evidence to optimise secondary prevention
How can Life Sciences better identify and treat the patients who benefit most from secondary prevention? In this 60-minute masterclass, LSE Professor Panos Kanavos explores how population health analytics, integrated care pathways and real-world uptake data can optimise access and outcomes.
NICE Advice: The impact of the new cost effectiveness threshold
Understand the implications: Explore how NICE’s new threshold changes could reshape pricing, access, launch strategy and innovation
As NICE’s cost-effectiveness framework evolves, understanding the wider implications has never been more important. Join John Spoors from NICE’ Commercial Managed Access and Medicines Policy (CMAP) team as he explores how the new threshold changes could impact pricing, reimbursement, launch sequencing, patient access and the future of innovation in the UK.